Miller KD - Search Results

1

Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.

Jagsi R, Mason G, Overmoyer BA, Woodward WA, Badve S, Schneider RJ, Lang JE, Alpaugh M, Williams KP, Vaught D, Smith A, Smith K, Miller KD; Susan G. Komen-IBCRF IBC Collaborative in partnership with the Milburn Foundation. Jagsi R, et al. Among authors: miller kd. Breast Cancer Res Treat. 2022 Apr;192(2):235-243. doi: 10.1007/s10549-021-06434-x. Epub 2022 Jan 1. Breast Cancer Res Treat. 2022. PMID: 34973083 Free PMC article. Review.

2

Taxanes in the treatment of breast cancer: a prodigy comes of age.

Miller KD, Sledge GW Jr. Miller KD, et al. Cancer Invest. 1999;17(2):121-36. Cancer Invest. 1999. PMID: 10071597 Review.

3

Breast cancer: challenges and opportunities.

Sledge GW Jr, Miller K. Sledge GW Jr, et al. Semin Oncol. 1999 Dec;26(6 Suppl 18):1-5. Semin Oncol. 1999. PMID: 10892573 Review.

4

Issues and challenges for antiangiogenic therapies.

Miller KD. Miller KD. Breast Cancer Res Treat. 2002 Oct;75 Suppl 1:S45-50; discussion S57-8. doi: 10.1023/a:1020317917759. Breast Cancer Res Treat. 2002. PMID: 12353823 Review.

5

E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer.

Miller KD. Miller KD. Clin Breast Cancer. 2003 Feb;3(6):421-2. doi: 10.3816/CBC.2003.n.007. Clin Breast Cancer. 2003. PMID: 12636887 No abstract available.

6

EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.

Lu M, Miller KD, Gokmen-Polar Y, Jeng MH, Kinch MS. Lu M, et al. Among authors: miller kd. Cancer Res. 2003 Jun 15;63(12):3425-9. Cancer Res. 2003. PMID: 12810680

7

Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer.

Kumar S, Kishimoto H, Chua HL, Badve S, Miller KD, Bigsby RM, Nakshatri H. Kumar S, et al. Among authors: miller kd. Am J Pathol. 2003 Dec;163(6):2531-41. doi: 10.1016/s0002-9440(10)63608-5. Am J Pathol. 2003. PMID: 14633625 Free PMC article.

8

A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer.

Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, Sparano JA, Wolff AC, Cobleigh MA, Galbraith S, Sledge GW. Miller KD, et al. Clin Cancer Res. 2004 Mar 15;10(6):1971-5. doi: 10.1158/1078-0432.ccr-03-0968. Clin Cancer Res. 2004. PMID: 15041714 Clinical Trial.

9

Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?

Miller KD. Miller KD. Breast Cancer Res. 2004;6(3):128-32. doi: 10.1186/bcr782. Epub 2004 Mar 18. Breast Cancer Res. 2004. PMID: 15084233 Free PMC article. Review.

10

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Miller KD, et al. J Clin Oncol. 2005 Feb 1;23(4):792-9. doi: 10.1200/JCO.2005.05.098. J Clin Oncol. 2005. PMID: 15681523 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

516 results

Search Page